Tandem Capital Management Corp ADV Buys 1,058 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Tandem Capital Management Corp ADV increased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 2.8% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 38,851 shares of the life sciences company’s stock after buying an additional 1,058 shares during the quarter. Tandem Capital Management Corp ADV’s holdings in Integra LifeSciences were worth $1,692,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Swiss National Bank increased its position in Integra LifeSciences by 0.9% in the third quarter. Swiss National Bank now owns 161,994 shares of the life sciences company’s stock worth $6,187,000 after purchasing an additional 1,500 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new position in Integra LifeSciences in the third quarter worth approximately $43,034,000. Cardinal Capital Management raised its holdings in shares of Integra LifeSciences by 1.6% in the 4th quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after purchasing an additional 347 shares in the last quarter. Cooke & Bieler LP raised its position in shares of Integra LifeSciences by 4.4% in the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after acquiring an additional 120,410 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Integra LifeSciences in the 3rd quarter worth approximately $25,443,000. Institutional investors own 84.78% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on IART shares. Truist Financial decreased their price target on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price on the stock in a report on Wednesday, April 3rd. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Finally, JMP Securities decreased their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Stock Down 3.3 %

Shares of NASDAQ:IART traded down $0.97 during trading hours on Thursday, reaching $28.41. The stock had a trading volume of 1,581,135 shares, compared to its average volume of 705,624. Integra LifeSciences Holdings Co. has a 1 year low of $27.18 and a 1 year high of $56.41. The firm’s 50 day moving average is $35.67 and its 200-day moving average is $38.83. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of 34.23, a P/E/G ratio of 0.88 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The business had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.94 earnings per share. Research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.